Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Exectuive Moves: GlaxoSmithKline | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Exectuive Moves: GlaxoSmithKline

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Andrew Witty has been appointed chief executive officer designate, GlaxoSmithKline. Mr. Witty, currently president, Pharmaceuticals Europe for GSK, will succeed Dr. Jean-Pierre Garnier following his retirement as chief executive officer at the end of May 2008.

Sir Christopher Gent, chairman, GlaxoSmithKline said, “Andrew’s appointment follows a rigorous selection process by the board of directors. The fact that we have been able to select a successor to JP from three strong internal candidates is a testament to the quality of management at GSK. The Board is confident that Andrew will build on JP’s considerable achievements which have positioned GSK as a leader of the pharmaceutical industry.”

Dr. Garnier said, “Andrew has made many significant contributions to GSK and I am very pleased that he is to be our next CEO. I look forward to working with him during our handover and wish him every success.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters